FOR IMMEDIATE
RELEASE
Contact: Ron
Newby, Director of Marketing
(781) 647-3700
ext. 350
Download PDF of Press Release
Nova StatStrip
Glucose Hospital Meter System
Now Offers
Wireless Meter Connectivity
Only glucose meter FDA-cleared for use with all
patients,
including critically ill
Waltham,
MA –
May 7, 2015 - Nova Biomedical’s StatStrip Glucose
Hospital Meter System now offers bidirectional
wireless connectivity to the hospital’s HIS or LIS
with complete security to protect patient data.
StatStrip
Glucose’s wireless connectivity can transmit patient
results directly from the patient bedside,
alleviating the need to bring the meter to a fixed
location for meter docking and data transmission.
Wireless connectivity saves time for the caregiver
and allows for faster charting of results and
clinical decision making to improve patient care.
StatStrip Glucose’s dual-band wireless connectivity
provides complete security and encryption to ensure
that patient data remains uncompromised. Nova now
offers a full range of StatStrip Glucose wireless
connectivity capabilities, including wireless
meters, wireless carrying cases, and wireless
docking stations. All of the wireless devices use
industry standard POCT1-A2 data format and are
compatible with a choice of middleware partners.
StatStrip
Glucose is the only glucose meter cleared by the
U.S. Food and Drug Administration (FDA) for use with
all patients, in all healthcare settings, including
critical care. StatStrip Glucose received this
clearance in 2014 after an extensive, nearly
four-year study conducted at five major university
medical centers, which included 1,698 critically ill
patients with over 257 clinical conditions. Over
8,000 medications were investigated for potential
interference to StatStrip Glucose measurement.
StatStrip Glucose demonstrated excellent agreement
compared to central laboratory reference methods and
no clinical interferences were found.
In
addition to the study submitted to the FDA, 138
other independent studies over the last eight
years—including 53 critical care studies—have found
no clinically significant interferences for
StatStrip Glucose. This is a statement that no other
glucose meter manufacturer can make. StatStrip
Glucose is the world’s most extensively studied and
proven glucose test.
About
Nova Biomedical
Nova
Biomedical is a world leader in the development and
manufacturing of state-of-the-art, whole blood,
point-of-care and critical care analyzers, and is
one of the fastest growing in vitro diagnostic
companies in the world. Nova’s whole blood biosensor
technology is incorporated in products ranging from
handheld meters for glucose self- and point-of-care
testing to critical care whole blood analyzers
designed for rapid measurement of over 20 analytes.
Nova employs over 1,000 people worldwide and has
wholly owned subsidiaries located in Canada, France,
Germany, Great Britain, Japan, and Taiwan. Certified
by the International Organization for
Standardization, Nova has manufacturing operations
located in the U.S., Taiwan, and Brazil. |